Thus, an increased NRF2 expression/activity can represent a potential mechanism of resistance to pro-oxidant therapy since NRF2 can reduce 4-Hydroxynonenal sensitivity in prostate cancer cells. This evidence concerns the gene NFE2L2 and prostate carcinoma.